Elisa Giovannetti, MD, PhD. received her M.D. and Ph.D. with full marks and from the University of Pisa, Italy, in 2000 and 2007, respectively. Between 2001 and 2004, she contributed to translational studies on pharmacogenetics as clinical fellow in Pharmacology in the Department of Oncology of Pisa University. Since 2006 she collaborated with the Department of Medical Oncology at VU University Medical Center (VUmc), Amsterdam, The Netherlands, to set-up a line of research on (epi)genetic determinants of drug activity and molecular mechanisms underlying chemoresistance in pancreatic and lung cancer. She was promoted to Associate Professor in 2016, received the habilitation as Full Professor in 2022, and she is also working as PI of a Start-Up lab at the Fondazione Pisana per la Scienza, Pisa, Italy. Her current research interests include also the role of liquid biopsies in early diagnosis and prediction of drug activity. She is actively involved, as elected chair, in research projects within the “Pharmacology and Molecular Mechanism Group” group of the EORTC (EORTC-PAMM), as well as in the European Pancreatic Club (EPC). She successfully requested funding from the Netherlands Organization for Scientific Research (NWO, VENI grant), “Marie Curie” and COST European Initiatives (H2020-MSCA-RISE “Alise” and COST “Stratagem”), Italian Association for Research against Cancer (AIRC, Start-Up and IG grants), Cancer Center Amsterdam (CCA) Foundation, and Dutch Cancer Society (KWF). Dr. Giovannetti is author or co-author of >350 scientific publications in peer reviewed journals, with an H-index of 64 (Google Scholar), she has been invited for >130 Selected/Invited Lectures in international meetings, seminars and webinars and she is Deputy Editor of Critical Reviews in Oncology and Hematology, Associate Editor of Cancer Chemotherapy and Pharmacology, Cellular Oncology, Cancers, and Journal of Chemotherapy.